3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Rectal Neoplasms
2
Uveal Melanoma
1
Smoking Cessation
1
Prostatic Neoplasms
1
Prostate Adenocarcinoma
1
Multiple Myeloma
1
Motor Activity
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Ipilimumab
10
pembrolizumab
7
Nivolumab
7
incomplete Freund's adjuvant
6
Temozolomide
5
Dacarbazine
5
tebentafusp
4
Sunitinib
4
MART-1 Antigen
4
Carboplatin
4
CTLA-4 Antigen
4
sargramostim
3
montanide ISA 51
3
aflibercept
3
Paclitaxel
3
Bevacizumab
3
trametinib
2
relatlimab
2
olaparib
2
lenvatinib
2
cediranib
2
Vorinostat
2
Thalidomide
2
Taxes
2
Sorafenib
2
Radiosurgery
2
MAGEA3 protein, human
2
Lenalidomide
2
Interleukin-2
2
Interleukin-12 Subunit p35
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Uveal Melanoma
×
Diet Therapy
×
Clear all
NCT04645680
2026-01-30
DIET
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
50 enrolled